Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2022 Jan 15;399(10321):212-213.
doi: 10.1016/S0140-6736(21)02834-8. Epub 2021 Dec 23.

Efficacy of an adenovirus type 5 vectored SARS-CoV-2 vaccine

Richard B Kennedy  1
Affiliations
Comment

Efficacy of an adenovirus type 5 vectored SARS-CoV-2 vaccine

Richard B Kennedy. Lancet. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

I report being the inventor of and holding a patent for SARS-CoV-2 PolyPeptides and receiving royalties paid by Initiatives to Change the World (ICW) Healthcare Ventures for this patent and other intellectual property covering the development of peptide-based vaccines.

Comment on

References

    1. Peacocke EF, Heupink LF, Frønsdal K, Dahl EH, Chola L. Global access to COVID-19 vaccines: a scoping review of factors that may influence equitable access for low and middle-income countries. BMJ Open. 2021;11 - PMC - PubMed
    1. McAteer J, Yildirim I, Chahroudi A. The VACCINES act: deciphering vaccine hesitancy in the time of COVID-19. Clin Infect Dis. 2020;71:703–705. - PMC - PubMed
    1. Halperin SA, Ye L, MacKinnon-Cameron D, et al. Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blinded, placebo-controlled phase 3 trial. Lancet. 2021 doi: 10.1016/S0140-6736(21)02753-7. published online Dec 23. - DOI - PMC - PubMed
    1. Voysey M, Clemens SAC, Madhi SA, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397:99–111. - PMC - PubMed
    1. Sadoff J, Le Gars M, Shukarev G, et al. Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine. N Engl J Med. 2021;384:1824–1835. - PMC - PubMed

Substances